Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Progesterone vaginal ring · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | 1 ring intravaginal for 7 days, produced from the new process |
| Treatment B | EXPERIMENTAL | 1 ring intravaginal for 7 days, produced from the legacy process |
| Name | Type | Description |
|---|---|---|
| Progesterone vaginal ring, | DRUG | Participants will be randomized to receive treatments in 1 of 2 treatment sequences (AB or BA) |
Inclusion: 1. Naturally postmenopausal woman with an intact uterus, 40 to 70 years of age, inclusive. 2. The subject has serum estradiol and FSH levels that are consistent with the subject being postmenopausal. 3. The subject has no clinically significant abnormality findings observed during pelvic...
Progesterone vaginal ring is an investigational small molecule therapeutic developed by Teva Pharmaceutical Industries Limited. It is designed to deliver progesterone through a vaginal ring dosage form. The specific medical indication for this product has not been publicly disclosed, and the program remains in Phase 1 clinical development.
Progesterone vaginal ring targets the progesterone receptor, also known as PGR, where it acts as an agonist. By binding and activating PGR, the ring delivers a progestational effect through the vaginal route. This receptor is the same biological target engaged by other progesterone-based therapies.
Progesterone vaginal ring is being developed by Teva Pharmaceutical Industries Limited, which trades on the New York Stock Exchange under the ticker TEVA. Teva is the sponsor responsible for the clinical development program for this investigational product.
Progesterone vaginal ring is in Phase 1 clinical development. It is an investigational product and has not been approved by the FDA. The program has completed one Phase 1 trial, and no active trials are currently listed for this asset.
Progesterone vaginal ring has been studied in one completed Phase 1 trial, NCT02092571, titled A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal Women. The trial enrolled 56 female participants aged 40 years and older in the United States and was randomized and controlled.
Progesterone vaginal ring is also referred to simply as progesterone vaginal ring. It is a distinct investigational vaginal ring formulation developed by Teva, not a generic oral progesterone product. Its identity is defined by the vaginal ring delivery system and the specific pharmacokinetic profile studied in NCT02092571.